The advances in targeting CD47/SIRPα "do not eat me" axis and their ongoing challenges as an anticancer therapy.
作者信息
Gracia-Hernandez Maria, Suresh Manasa, Villagra Alejandro
出版信息
Oncotarget. 2024 Jul 10;15:462-465. doi: 10.18632/oncotarget.28607.
Abstract
摘要
相似文献
1
The advances in targeting CD47/SIRPα "do not eat me" axis and their ongoing challenges as an anticancer therapy.靶向CD47/SIRPα“别吃我”轴的研究进展及其作为抗癌疗法面临的持续挑战。
Oncotarget. 2024 Jul 10;15:462-465. doi: 10.18632/oncotarget.28607.
2
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.抗肿瘤治疗中针对 CD47/SIRPα 轴的研究进展。
Front Immunol. 2020 Jan 28;11:18. doi: 10.3389/fimmu.2020.00018. eCollection 2020.
3
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.SIRPα-CD47 免疫检查点阻断在癌症治疗中的应用。
Trends Immunol. 2018 Mar;39(3):173-184. doi: 10.1016/j.it.2017.12.005. Epub 2018 Jan 11.
4
The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?microRNAs 与传统细胞毒药物联合调控 CD47-SIRPα 信号轴并结合纳米递药系统：治疗的选择？
Mol Biol Rep. 2021 Jul;48(7):5707-5722. doi: 10.1007/s11033-021-06547-y. Epub 2021 Jul 17.
5
Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.CD47 免疫检查点阻断剂在抗肿瘤治疗中的研究进展：血液毒性方面
J Cancer Res Clin Oncol. 2022 Jan;148(1):1-14. doi: 10.1007/s00432-021-03815-z. Epub 2021 Oct 5.
6
"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.作为信号调节蛋白α（SIRPα）拮抗剂的高亲和力CD47胞外域的“维可牢”工程，可增强抗体依赖性细胞吞噬作用。
J Biol Chem. 2015 May 15;290(20):12650-63. doi: 10.1074/jbc.M115.648220. Epub 2015 Apr 2.
7
Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.阻断 CD47-SIRPα“别吃我”信号在血液系统恶性肿瘤中的研究进展。
Blood Rev. 2018 Nov;32(6):480-489. doi: 10.1016/j.blre.2018.04.005. Epub 2018 Apr 14.
8
An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.一种靶向CD47的抗肿瘤肽RS17：设计、合成及抗肿瘤活性
Cancer Med. 2021 Mar;10(6):2125-2136. doi: 10.1002/cam4.3768. Epub 2021 Feb 24.
9
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.ADU-1805 是一种选择性的全等位基因抗 SIRPα 抗体，可阻断 SIRPα-CD47 固有免疫检查点，对其功能进行了鉴定。
J Immunother Cancer. 2019 Dec 4;7(1):340. doi: 10.1186/s40425-019-0772-0.
10
Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer.铂(IV)配合物作为 CD47-SIRPα 轴抑制剂用于癌症的化免疫治疗。
Eur J Med Chem. 2022 Feb 5;229:114047. doi: 10.1016/j.ejmech.2021.114047. Epub 2021 Dec 7.
引用本文的文献
1
CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.CD200R1-CD200 检查点与 SIRPα-CD47 不同，它通过抑制吞噬作用来抑制肿瘤生长。
Nat Commun. 2025 Jun 3;16(1):5145. doi: 10.1038/s41467-025-60456-3.
本文引用的文献
1
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.靶向治疗使致癌基因驱动的肺癌对巨噬细胞介导的破坏敏感。
J Clin Invest. 2024 Mar 14;134(9):e169315. doi: 10.1172/JCI169315.
2
Targeting HDAC6 improves anti-CD47 immunotherapy.靶向 HDAC6 可增强抗 CD47 免疫疗法。
J Exp Clin Cancer Res. 2024 Feb 27;43(1):60. doi: 10.1186/s13046-024-02982-4.
3
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.开发和评估一种用于曲妥珠单抗耐药乳腺癌免疫治疗的人源 CD47/HER2 双特异性抗体。
Drug Resist Updat. 2024 May;74:101068. doi: 10.1016/j.drup.2024.101068. Epub 2024 Feb 13.
4
Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy.CD47 靶向治疗在癌症免疫治疗中的机遇与挑战。
Oncol Res. 2023 Nov 15;32(1):49-60. doi: 10.32604/or.2023.042383. eCollection 2023.
5
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.抗 CD47 抗体的抗肿瘤活性需要 Fc-FcγR 相互作用。
Cancer Cell. 2023 Dec 11;41(12):2051-2065.e6. doi: 10.1016/j.ccell.2023.10.007. Epub 2023 Nov 16.
6
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.靶向CD47-SIRPa轴作为单一疗法显示出强大的临床前抗肿瘤活性，并与PARP抑制协同作用。
NPJ Precis Oncol. 2023 Jul 19;7(1):69. doi: 10.1038/s41698-023-00418-4.
7
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives.基于癌症中CD47疗法的核心：联合策略、机制及未来展望
Acta Pharm Sin B. 2023 Apr;13(4):1467-1487. doi: 10.1016/j.apsb.2022.12.016. Epub 2022 Dec 26.
8
Emerging phagocytosis checkpoints in cancer immunotherapy.癌症免疫治疗中的新兴吞噬检查点。
Signal Transduct Target Ther. 2023 Mar 7;8(1):104. doi: 10.1038/s41392-023-01365-z.
9
The landscape overview of CD47-based immunotherapy for hematological malignancies.基于CD47的血液系统恶性肿瘤免疫治疗全景概述。
Biomark Res. 2023 Feb 1;11(1):15. doi: 10.1186/s40364-023-00456-x.
10
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.泰达西那林（CI-994），一种 I 类 HDAC 抑制剂，针对 MYC 驱动的髓母细胞瘤中的内在肿瘤生长和软脑膜播散，同时通过 NF-kB-TGM2 驱动的肿瘤炎症使它们易受抗 CD47 诱导的巨噬细胞吞噬作用。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005871.
Zotero 插件